SCHEMBL7130625

SCHEMBL7130625

CCCCOc1c(C(=O)O)ccc2c1C(S(=O)(=O)c1ccccc1)CS2(O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.36
KAT6A Q92794 1/20 0.35
S1PR3 Q99500 2/20 0.34
PTPN11 Q06124 2/20 0.34
MAPK8 P45983 1/20 0.34
CCNE2 O96020 2/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
TSHR P16473 2/20 0.33
METAP2 P50579 1/20 0.33
ABCB1 P08183 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PTGS2 P35354 1/20 0.32
POLB P06746 1/20 0.32
PLK1 P53350 1/20 0.32
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134743 0.96 S1PR3 (0.40) S1PR3PTPN11MAPK8CCNE2CCNE1
SCHEMBL7129218 0.96 S1PR3 (0.40) S1PR3PTPN11MAPK8CCNE2CCNE1
SCHEMBL7130170 0.91 CYP1A2 (0.36) WDR5KAT6ACCNE2CCNE1CDK2
SCHEMBL7126404 0.91 ACLY (0.33) WDR5KAT6AMAPK8TSHRALDH1A1
SCHEMBL7130631 0.90 CA9 (0.36) WDR5KAT6AS1PR3PTPN11MAPK8
SCHEMBL7127953 0.88 L3MBTL1 (0.47) KAT6ATSHRALDH1A1POLBTDP1
SCHEMBL7135490 0.88 HDAC3 (0.37) KAT6AS1PR3CCNE2CCNE1CDK2
SCHEMBL7133399 0.88 HDAC3 (0.37) KAT6AS1PR3CCNE2CCNE1CDK2
SCHEMBL7127472 0.87 HPGD (0.41) TSHRALDH1A1L3MBTL1
SCHEMBL7129219 0.86 S1PR3 (0.40) S1PR3PTPN11MAPK8CCNE2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO WDR5 3447/4885KAT6A 4261/4885S1PR3 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.